131 related articles for article (PubMed ID: 21030044)
21. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E
Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013
[TBL] [Abstract][Full Text] [Related]
22. Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation.
Miyake H; Kurahashi T; Yamanaka K; Kondo Y; Takenaka A; Inoue TA; Fujisawa M
BJU Int; 2010 Dec; 106(11):1643-7. PubMed ID: 20553261
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
Bukowski RM; Stadler WM; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Figlin RA
Oncology; 2010; 78(5-6):340-7. PubMed ID: 20733337
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
Bilaç C; Müezzinoğlu T; Ermertcan AT; Kayhan TC; Temeltaş G; Oztürkcan S; Temiz P
Cutan Ocul Toxicol; 2009; 28(2):90-2. PubMed ID: 19514932
[TBL] [Abstract][Full Text] [Related]
26. Biochemical modulation of 5-fluorouracil with interferon alpha/beta and gamma on murine renal cell carcinoma.
Ishii T; Marumo K
Int J Urol; 2004 Nov; 11(11):993-1000. PubMed ID: 15509204
[TBL] [Abstract][Full Text] [Related]
27. Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production.
Kats-Ugurlu G; Maass C; van Herpen C; de Waal R; Oosterwijk E; Mulders P; Hulsbergen-van de Kaa C; Leenders W
Histopathology; 2011 Sep; 59(3):562-4. PubMed ID: 22034894
[No Abstract] [Full Text] [Related]
28. Transient perforating folliculitis induced by sorafenib.
Minami-Hori M; Ishida-Yamamoto A; Komatsu S; Iiduka H
J Dermatol; 2010 Sep; 37(9):833-4. PubMed ID: 20883372
[No Abstract] [Full Text] [Related]
29. [Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].
Xie XD; Piao Y; Liu ZZ
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):714-5. PubMed ID: 20021872
[No Abstract] [Full Text] [Related]
30. Sorafenib.
Hahn O; Stadler W
Curr Opin Oncol; 2006 Nov; 18(6):615-21. PubMed ID: 16988583
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib: delivering a targeted drug to the right targets.
Flaherty KT
Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
[TBL] [Abstract][Full Text] [Related]
32. Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
Zhang HL; Zhu Y; Wang CF; Yao XD; Zhang SL; Dai B; Shen YJ; Zhu YP; Shi GH; Ye DW
Int J Urol; 2011 Jun; 18(6):422-30. PubMed ID: 21481012
[TBL] [Abstract][Full Text] [Related]
33. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
[TBL] [Abstract][Full Text] [Related]
34. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
[TBL] [Abstract][Full Text] [Related]
35. Effect of interferon-alpha A/D in combination with the Japanese and Chinese traditional herbal medicine juzen-taiho-to on lung metastasis of murine renal cell carcinoma.
Muraishi Y; Mitani N; Yamaura T; Fuse H; Saiki I
Anticancer Res; 2000; 20(5A):2931-7. PubMed ID: 11062703
[TBL] [Abstract][Full Text] [Related]
36. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Ratain MJ; Eisen T; Stadler WM; Flaherty KT; Kaye SB; Rosner GL; Gore M; Desai AA; Patnaik A; Xiong HQ; Rowinsky E; Abbruzzese JL; Xia C; Simantov R; Schwartz B; O'Dwyer PJ
J Clin Oncol; 2006 Jun; 24(16):2505-12. PubMed ID: 16636341
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
Eng FC; Easson AM; Szentgyorgyi E; Knox JJ
Eur J Surg Oncol; 2009 Feb; 35(2):219-21. PubMed ID: 17976949
[No Abstract] [Full Text] [Related]
39. Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report.
Sciarra A; Autran Gomez AM; Gentilucci A; Parente U; Salciccia S; Gentile V; Di Silverio F
Eur Urol; 2007 Aug; 52(2):597-9. PubMed ID: 17420088
[TBL] [Abstract][Full Text] [Related]
40. Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10.
Di Lorenzo G
Eur Urol; 2007 Sep; 52(3):926-8; author reply 928. PubMed ID: 17574728
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
